{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:08:18Z","timestamp":1791151698726,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T00:00:00Z","timestamp":1382918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2334-13-502","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T14:01:50Z","timestamp":1382968910000},"source":"Crossref","is-referenced-by-count":26,"title":["Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies"],"prefix":"10.1186","volume":"13","author":[{"given":"Darrell Hoi-San","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Lynn","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,28]]},"reference":[{"key":"2709_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/OLQ.0b013e31818d3fb6","volume":"36","author":"B Romanowski","year":"2008","unstructured":"Romanowski B, Myziuk LN, Walmsley SL, Trottier S, Singh AE, Houston S, Joffe M, Chiu I: Seroprevalence and risk factors for Herpes Simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis. 2008, 36: 165-169.","journal-title":"Sex Transm Dis"},{"key":"2709_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1086\/382750","volume":"189","author":"RH Gray","year":"2004","unstructured":"Gray RH, Li X, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Kiwanuka N, Kigozi G, Nalugoda F, et al: Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis. 2004, 189: 1209-1215. 10.1086\/382750.","journal-title":"J Infect Dis"},{"key":"2709_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1086\/315339","volume":"181","author":"RH Lyles","year":"2000","unstructured":"Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Margolick JB, Phair JP, Mellors JW: Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000, 181: 872-880. 10.1086\/315339.","journal-title":"J Infect Dis"},{"key":"2709_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/505496","volume":"43","author":"LB Strick","year":"2006","unstructured":"Strick LB, Wald A, Celum C: Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis. 2006, 43: 347-356. 10.1086\/505496.","journal-title":"Clin Infect Dis"},{"key":"2709_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1473-3099(12)70037-3","volume":"12","author":"SJ Reynolds","year":"2012","unstructured":"Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, et al: Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis. 2012, 12: 441-448. 10.1016\/S1473-3099(12)70037-3.","journal-title":"Lancet Infect Dis"},{"key":"2709_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(09)62038-9","volume":"375","author":"JR Lingappa","year":"2010","unstructured":"Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, et al: Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010, 375: 824-833. 10.1016\/S0140-6736(09)62038-9.","journal-title":"Lancet"},{"key":"2709_CR7","doi-asserted-by":"publisher","first-page":"31289","DOI":"10.1074\/jbc.C800188200","volume":"283","author":"MA McMahon","year":"2008","unstructured":"McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem. 2008, 283: 31289-31293. 10.1074\/jbc.C800188200.","journal-title":"J Biol Chem"},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2008.07.008","volume":"4","author":"A Lisco","year":"2008","unstructured":"Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, Elliott J, Fromentin E, Shattock R, Anton P, et al: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe. 2008, 4: 260-270. 10.1016\/j.chom.2008.07.008.","journal-title":"Cell Host Microbe"},{"key":"2709_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007, 147: 573-577. 10.7326\/0003-4819-147-8-200710160-00010.","journal-title":"Ann Intern Med"},{"key":"2709_CR10","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007, 147: W163-W194.","journal-title":"Ann Intern Med"},{"key":"2709_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ije\/dym018","volume":"36","author":"S Sanderson","year":"2007","unstructured":"Sanderson S, Tatt ID, Higgins JP: Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007, 36: 666-676. 10.1093\/ije\/dym018.","journal-title":"Int J Epidemiol"},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/QAI.0b013e31821acb5","volume":"57","author":"RV Barnabas","year":"2011","unstructured":"Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, et al: Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr. 2011, 57: 238-244. 10.1097\/QAI.0b013e31821acb5.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2709_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1086\/513568","volume":"195","author":"ER Cachay","year":"2007","unstructured":"Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ: Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection [see comment]. J Infect Dis. 2007, 195: 1270-1277. 10.1086\/513568.","journal-title":"J Infect Dis"},{"key":"2709_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/QAI.0b013e318163bd87","volume":"47","author":"ER Cachay","year":"2008","unstructured":"Cachay ER, Frost SDW, Poon AFY, Looney D, Rostami SM, Pacold ME, Richman DD, Little SJ, Smith DM: Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels. J Acquir Immune Defic Syndr. 2008, 47: 592-596. 10.1097\/QAI.0b013e318163bd87.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2709_CR15","volume-title":"44th Annual Meeting of IDSA: 12-15 October 2006; Abstract 895","author":"N Crum-Cianflone","year":"2006","unstructured":"Crum-Cianflone N, Hale B, Truett A, Utz G, Chun H, Pope B, Burgi A, Medina S, Brandt C, Furtek K, et al: The effect of herpes simplex virus 2 (HSV2) co-infection in HIV-infected persons on CD4 counts, HIV viral load, and time to antiretroviral medications. 44th Annual Meeting of IDSA: 12-15 October 2006; Abstract 895. 2006, Toronto, Canada: Alexandria: Infectious Diseases Society of America"},{"key":"2709_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/589621","volume":"198","author":"N Nagot","year":"2008","unstructured":"Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, Sanon A, Becquart P, Segondy M, Sawadogo A, et al: Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008, 198: 241-249. 10.1086\/589621.","journal-title":"J Infect Dis"},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"e19947","DOI":"10.1371\/journal.pone.0019947","volume":"6","author":"AC Roxby","year":"2011","unstructured":"Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, Farquhar C: Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One. 2011, 6: e19947-10.1371\/journal.pone.0019947.","journal-title":"PLoS One"},{"key":"2709_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00002030-200101050-00024","volume":"15","author":"B Suligoi","year":"2001","unstructured":"Suligoi B, Dorrucci M, Volpi A, Andreoni M, Pezzotti P, Rezza G, Italian Seroconversion S: Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. AIDS. 2001, 15: 133-135. 10.1097\/00002030-200101050-00024.","journal-title":"AIDS"},{"key":"2709_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/QAD.0b013e328347fa37","volume":"25","author":"C Ludema","year":"2011","unstructured":"Ludema C, Cole SR, Poole C, Chu H, Eron JJ: Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS. 2011, 25: 1265-1269. 10.1097\/QAD.0b013e328347fa37.","journal-title":"AIDS"},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1086\/515621","volume":"178","author":"JP Ioannidis","year":"1998","unstructured":"Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, et al: Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis. 1998, 178: 349-359. 10.1086\/515621.","journal-title":"J Infect Dis"},{"key":"2709_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00007435-200304000-00007","volume":"30","author":"R Ashley-Morrow","year":"2003","unstructured":"Ashley-Morrow R, Krantz E, Wald A: Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis. 2003, 30: 310-314. 10.1097\/00007435-200304000-00007.","journal-title":"Sex Transm Dis"},{"key":"2709_CR22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/JCM.26.4.662-667.1988","volume":"26","author":"RL Ashley","year":"1988","unstructured":"Ashley RL, Militoni J, Lee F, Nahmias A, Corey L: Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988, 26: 662-667.","journal-title":"J Clin Microbiol"},{"key":"2709_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.olq.0000187211.61052.c7","volume":"33","author":"M Ramaswamy","year":"2006","unstructured":"Ramaswamy M, Sabin C, McDonald C, Smith M, Taylor C, Geretti AM: Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sex Transm Dis. 2006, 33: 96-101. 10.1097\/01.olq.0000187211.61052.c7.","journal-title":"Sex Transm Dis"},{"key":"2709_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.7326\/0003-4819-121-11-199412010-00004","volume":"121","author":"J Benedetti","year":"1994","unstructured":"Benedetti J, Corey L, Ashley R: Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994, 121: 847-854. 10.7326\/0003-4819-121-11-199412010-00004.","journal-title":"Ann Intern Med"},{"key":"2709_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7326\/0003-4819-131-1-199907060-00004","volume":"131","author":"JK Benedetti","year":"1999","unstructured":"Benedetti JK, Zeh J, Corey L: Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med. 1999, 131: 14-20. 10.7326\/0003-4819-131-1-199907060-00004.","journal-title":"Ann Intern Med"},{"key":"2709_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00007435-200302000-00015","volume":"30","author":"R Engelberg","year":"2003","unstructured":"Engelberg R, Carrell D, Krantz E, Corey L, Wald A: Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis. 2003, 30: 174-177. 10.1097\/00007435-200302000-00015.","journal-title":"Sex Transm Dis"},{"key":"2709_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1056\/NEJM199509213331205","volume":"333","author":"A Wald","year":"1995","unstructured":"Wald A, Zeh J, Selke S, Ashley RL, Corey L: Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995, 333: 770-775. 10.1056\/NEJM199509213331205.","journal-title":"N Engl J Med"},{"key":"2709_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1086\/517297","volume":"176","author":"L Mole","year":"1997","unstructured":"Mole L, Ripich S, Margolis D, Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997, 176: 766-770. 10.1086\/517297.","journal-title":"J Infect Dis"},{"key":"2709_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0009973","volume":"5","author":"B Aumakhan","year":"2010","unstructured":"Aumakhan B, Gaydos CA, Quinn TC, Beyrer C, Benning L, Minkoff H, Merenstein DJ, Cohen M, Greenblatt R, Nowicki M, et al: Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One. 2010, 5: 1-7.","journal-title":"PLoS One"},{"key":"2709_CR30","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/infdis\/jir649","volume":"204","author":"K Mugwanya","year":"2011","unstructured":"Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C: High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1\/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis. 2011, 204: 1912-1917. 10.1093\/infdis\/jir649.","journal-title":"J Infect Dis"},{"key":"2709_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/infdis\/jiq013","volume":"203","author":"JM Baeten","year":"2011","unstructured":"Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, et al: Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1\/HSV-2 dually infected persons. J Infect Dis. 2011, 203: 117-121. 10.1093\/infdis\/jiq013.","journal-title":"J Infect Dis"},{"key":"2709_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/aid.2012.0071","volume":"29","author":"AC Roxby","year":"2013","unstructured":"Roxby AC, Liu AY, Drake AL, Kiarie JN, Richardson B, Lohman-Payne BL, John-Stewart GC, Wald A, De Rosa S, Farquhar C: Short communication: T cell activation in HIV-1\/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir. AIDS Res Hum Retroviruses. 2013, 29: 94-98. 10.1089\/aid.2012.0071.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2709_CR33","volume-title":"Clin Infect Dis","author":"TJ Yi","year":"2013","unstructured":"Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DHS: A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV\/Herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis. 2013, epub ahead of print"},{"key":"2709_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1469-0691.2004.00836.x","volume":"10","author":"R Ashley-Morrow","year":"2004","unstructured":"Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J: Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect. 2004, 10: 530-536. 10.1111\/j.1469-0691.2004.00836.x.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-502\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T22:12:47Z","timestamp":1596751967000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-502","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,28]]},"article-number":"502"}}